Why would Walmart launch an insurance education service for the 140 million Americans who shop its stores each week? For one thing, because more than 60% of Americans have a tough time understanding their health insurance plan options, according to research from the Kaiser Family Foundation, and nearly 40% feel that they picked the wrong plan after enrolling.
The retail behemoth that is Wal-Mart Stores Inc. is fixing its sights on a new target: the nation’s overstretched and overly costly primary healthcare system. The result could be a major disruption of that system and the acceleration of health reform in America.
Global responsibility and sustainability continue to be priorities for Walmart Stores. The company filed its proxy statement ahead of its June 5 annual shareholders meeting, and also issued its annual report, and the 2015 Global Responsibility Report and Global Compliance Program Report.
“Our health-and-wellness experts are leading the way for the future of health care in our stores and beyond.”
For any retail pharmacy provider, that would be a bold, perhaps even overly confident, assertion. But coming as it does from Walmart, it’s something that both the U.S. healthcare system and Walmart’s competitors are taking seriously.
Walmart’s share price will be under pressure in the coming years as a holding company created decades ago by the Walton family to control their ownership of the company prepares to unload as much as 6% of Walmart’s outstanding shares.
Onco360 on Monday announced that it has been selected by Pfizer as a limited-distribution pharmacy network participant for Ibrance (palbociclib), Pfizer’s recently approved product for certain breast cancers.